← The Wire
COGTNasdaq
Cogent Biosciences, Inc.
Pharmaceutical Preparations · DE · CIK 1622229
Develops precision therapies for genetically defined diseases by designing rational treatments for underlying causes
$5.66B
Market cap
$38.74
Last close
+1.7%
1D
+8.1%
5D
3.2M
Volume
Price · last 39 sessions+5.5%
May 4L $31.02 · H $38.74Jun 29
190
Total filings
Jun 11, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 11, 202610-Q10-QMay 5, 20268-KResults of OperationsMay 5, 2026DEFA14ADEFA14AApr 23, 2026DEF 14ADEF 14AApr 23, 2026SC 13D/ASC 13D/AMar 31, 202610-K10-KFeb 17, 20268-KResults of OperationsFeb 17, 2026SC 13D/ASC 13D/AJan 22, 20268-KCompany UpdateDec 8, 20258-KMaterial Agreement · New Debt / ObligationNov 18, 20258-KMaterial Agreement · Company UpdateNov 13, 2025424B5424B5Nov 12, 2025424B5424B5Nov 12, 2025424B5424B5Nov 12, 2025424B5424B5Nov 12, 20258-KReg FD Disclosure · Company UpdateNov 10, 202510-Q10-QNov 7, 20258-KResults of OperationsNov 3, 20258-KMaterial Agreement · New Debt / ObligationSep 11, 202510-Q10-QAug 5, 20258-KResults of OperationsAug 5, 20258-KMaterial Agreement · Results of OperationsJul 10, 2025424B5424B5Jul 9, 2025424B5424B5Jul 8, 20258-KCompany UpdateJul 7, 20258-KMaterial Agreement · New Debt / ObligationJun 11, 20258-KBylaw Amendment · Shareholder VoteJun 5, 202510-Q10-QMay 6, 20258-KResults of OperationsMay 6, 2025424B5424B5May 6, 2025DEFA14ADEFA14AApr 22, 2025DEF 14ADEF 14AApr 22, 202510-K10-KFeb 25, 20258-KResults of OperationsFeb 25, 20258-KCompany UpdateDec 9, 202410-Q10-QNov 12, 20248-KResults of OperationsNov 12, 20248-KCompany UpdateSep 3, 202410-Q10-QAug 6, 20248-KResults of OperationsAug 6, 20248-KCompany UpdateJun 27, 20248-KBylaw Amendment · Shareholder VoteJun 5, 202410-Q10-QMay 7, 20248-KResults of OperationsMay 7, 2024DEFA14ADEFA14AApr 23, 2024DEF 14ADEF 14AApr 23, 20248-KEquity Issuance · Bylaw AmendmentMar 22, 202410-K10-KFeb 26, 20248-KResults of OperationsFeb 26, 2024SC 13GKYNAM CAPITAL MANAGEMENT, LPFeb 14, 20248-KMaterial Agreement · Equity IssuanceFeb 14, 2024SC 13GSCHEDULE 13GFeb 13, 2024SC 13GSC 13GFeb 9, 2024SC 13GSC 13GFeb 5, 20248-KCompany UpdateDec 11, 202310-Q10-QNov 7, 20238-KResults of OperationsNov 2, 202310-Q10-QAug 8, 20238-KResults of OperationsAug 8, 20238-KMaterial AgreementJun 8, 2023424B5424B5Jun 8, 20238-KExecutive Change · Shareholder VoteJun 7, 2023424B5424B5Jun 6, 20238-KCompany UpdateJun 6, 2023SC 13GCOGENT BIOSCIENCES, INC.Jun 1, 202310-Q10-QMay 9, 20238-KResults of OperationsMay 9, 2023DEFA14ADEFA14AApr 25, 2023DEF 14ADEF 14AApr 25, 202310-K10-KMar 14, 20238-KResults of OperationsMar 14, 2023SC 13GSC 13GFeb 3, 2023SC 13GSC 13GFeb 3, 20238-KReg FD DisclosureDec 12, 202210-Q10-QNov 14, 20228-KResults of OperationsNov 14, 2022SC 13GSC 13GSep 6, 202210-Q10-QAug 9, 20228-KResults of OperationsAug 9, 2022
Insider Activity
In the 90 days to Mar 31, 2026: 1 sold $370.0M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 31, 2026 | Fairmount Funds Management LlcDirector | Sell | 7,000,000 | $34.66 | $242.6M |
| Jan 22, 2026 | Fairmount Funds Management LlcDirector | Sell | 3,500,000 | $36.40 | $127.4M |
| Dec 26, 2025 | Robinson John EdwardChief Scientific Officer | Sell | 90,000 | $38.74 | $3.5M |
| Dec 26, 2025 | Sachs JessicaChief Medical Officer | Sell | 82,642 | $38.70 | $3.2M |
| Dec 26, 2025 | Green John L.Chief Financial Officer | Sell | 77,000 | $38.68 | $3.0M |
| Dec 26, 2025 | Kearns EvanChief Legal Officer | Sell | 65,000 | $38.70 | $2.5M |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance